Phase II trial shows epiretinal brachytherapy + bevacizumab improves VA

Article

NeoVista Inc?s epiretinal brachytherapy for wet AMD in combination with Avastin (bevacizumab) has been shown to improve mean visual acuity (VA) in patients, with adverse events restricted to vitrectomy-related problems and not to radiation toxicity, according to results of a Phase II trial presented at the 31st Annual Macula Society Meeting in Palm Beach, Florida, US.

NeoVista Inc's epiretinal brachytherapy for wet AMD in combination with Avastin (bevacizumab) has been shown to improve mean visual acuity (VA) in patients, with adverse events restricted to vitrectomy-related problems and not to radiation toxicity, according to results of a Phase II trial presented at the 31st Annual Macula Society Meeting in Palm Beach, Florida, US.

Researchers in the trial treated 34 eyes showing choroidal neovascularization (CNV) with an injection of Avastin, followed by a single dose (24 Gy) of the epiretinal brachytherapy. Patients received an additional dose of Avastin approximately one month later.

Thirty-three patients completed one year of follow-up, during which 76% required no further Avastin injections, and after which the mean VA improvement experienced was 10 letters on the ETDRS scale, with 94% losing fewer than 15 letters and 12% gaining 30 or more letters.

The next phase of the non-randomized, multicentre feasibility study, CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy), will be to evaluate the safety and efficacy of NeoVista's therapy with Lucentis (ranibizumab) versus Lucentis alone.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.